United States Blood Glucose Monitoring Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

United States Blood Glucose Monitoring Market Trends and Insights

Rising Diabetes Prevalence

CDC reported that 38.4 million Americans, or 11.6% of the population, lived with diabetes in 2025, while prevalence among adults 65+ climbed to 29.2%.^{[1]Centers for Disease Control and Prevention, “National Diabetes Statistics Report 2025,” cdc.gov} The burden is disproportionately heavy in Alabama, Mississippi, and Louisiana, where obesity exceeds 35% and endocrinology resources are sparse, spurring telehealth-enabled CGM demand. Direct medical costs totaled USD 307 billion in 2024; however, CGM uptake among Type 2 basal insulin users remained below 8%, highlighting untapped expansion opportunities. Prediabetes affects 97.6 million adults and carries a 70% risk of progressing to Type 2 within a decade, feeding a pipeline that sustains device volumes. Employer plans now reimburse CGM for prediabetic staff to avert downstream expenses, broadening the user base. Consequently, continuous monitoring is shifting from episodic testing toward universal surveillance across risk cohorts.

Technological Advances in CGM

Four sensor platforms received FDA clearance between March and September 2024, including Dexcom’s OTC Stelo, Abbott’s Lingo, Medtronic’s Simplera, and Senseonics’ 365-day Eversense. One-year implantability reduces adhesive dermatitis, which previously caused 18% of discontinuations within six months. Abbott’s partnership with Medtronic to embed Libre sensors into MiniMed pumps underscores the strategic importance of interoperability, enabling patients to assemble personalized hybrid solutions. Dexcom priced Stelo at USD 99 for a two-sensor month, demonstrating that retail shelves can reach the 30 million prediabetic Americans lacking prescription coverage. As wear duration stretches from 14 days to 365 days, per-day costs decrease toward USD 1, unlocking Medicaid and cash-pay segments that have been long tethered to USD 0.15 test strips.

Medicare Reimbursement Expansion

CMS lifted the intensive-insulin restriction in April 2023, extending CGM reimbursement to basal-insulin users and severe hypoglycemia cases, instantly adding 3.7 million beneficiaries.^{[2]Centers for Medicare & Medicaid Services, “National Coverage Determination for Continuous Glucose Monitors,” cms.gov} A Health Affairs review revealed that Florida, Arizona, and Pennsylvania accounted for 38% of incremental CGM claims, likely due to the presence of dense retiree populations. The standard USD 150 monthly payment created a USD 6.7 billion addressable pool, sparking vendor DTC campaigns. Fourteen Medicaid programs had mirrored the policy by 2025, although prior-authorization delays averaged 28 days. Hospital discharges now routinely include CGM prescriptions; a 2024 JAMA study linked this practice to a 41% drop in 30-day hypoglycemia ER visits. Early sales data suggest Medicare members represent the fastest-growing CGM cohort through 2026.

Interoperable “DIY Looping” Ecosystems

The FDA’s iCGM, ACE pump, and AID controller classes enable patients to pair devices from different brands, potentially leading to an estimated 15,000 U.S. DIY loopers by 2025. Tandem’s January 2024 cross-vendor integration of Abbott’s Libre 2 Plus with the t:slim X2 pump commercialized this modular vision. A Diabetes Care cohort study documented a jump in time-in-range from 68% to 76% and a 54% decrease in severe hypoglycemia among loopers, rivaling the annual savings of USD 10,000 compared to commercial systems.^{[3]American Diabetes Association, “Standards of Care in Diabetes 2024,” diabetesjournals.org} Community developers iterate algorithms within weeks, forcing incumbents to accelerate product cycles or cede tech-savvy Type 1 users. The framework decouples sensor, pump, and algorithm approvals, unlocking innovation but intensifying competitive churn.

High Cost of CGM Devices

Out-of-pocket CGM costs range from USD 1,200 to USD 2,400 annually, compared to USD 180 to USD 360 for SMBG, a six-fold premium that dissuades uninsured and high-deductible plan members. Survey work revealed that 34% of Type 2 users abandoned CGM within 90 days due to cost concerns, reverting to bulk-purchased strips at USD 0.15 each. Rebates negotiated by pharmacy benefit managers seldom reach the checkout counter, preserving the sticker shock of USD 300-400 per month. Dexcom’s USD 99 Stelo cuts the list price but shifts the full cost to consumers, limiting its reach. Rural counties with fewer than 50,000 residents post CGM adoption rates 62% below urban peers, magnifying health inequity.

Semiconductor Sensor Supply Risk

CGM ASICs are mostly fabricated in Taiwan, and 2024 lead times doubled to 26 weeks as foundries prioritized automotive chips. Medtronic’s Simplera clearance was delayed five months, missing the Medicare open-enrollment window. Deloitte modeled a four-week wafer outage translating into 18-22% sensor shortfalls, compelling rationing toward federally covered patients. Abbott’s Kilkenny facility mitigates risk yet will not operate at scale until late 2027. Roche's USD 550 million Indianapolis expansion follows the same onshoring logic.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Device Type: CGM Sensors Displace Legacy Glucometers

Self-monitoring systems captured 56.71% of the United States blood glucose monitoring market share in 2025, driven by three-year hospital contracts that bundled meters and strips at USD 0.80-1.20 per test. Test strips dominate revenue because basal insulin users typically burn through 730-1,095 strips annually, and proprietary chemistries help keep customers loyal. Lancets face commoditization, with generic units at USD 0.02 eroding branded margins. Conversely, CGM sensors are slated to post a 13.69% CAGR through 2031, fueled by 365-day implantables and OTC channels. Sensors account for about 72% of CGM revenue due to their steady replacement cadence, while transmitters are subsidized to secure subscription economics.

Glucometers persist in critical-care wards because the CGM mean absolute relative difference of 9-12% is outside the ±5% insulin-dosing tolerance FDA set in 2024. The reuse of strips and lancets still undercuts sensor economics in low-income homes, despite infection control warnings. The transition from 14-day to 365-day sensors reduces the daily cost and mitigates adhesive-related dropout, which is observed in 18% of patients within six months. Dexcom’s Stelo exploits prediabetes retail channels, while safety-engineered hospital lancets maintain a 40% premium due to OSHA mandates. 

By Patient Type: Type 1 Momentum Outpaces Type 2 Volume

Type 2 diabetes generated 62.27% revenue in 2025, but adoption of CGM among basal-insulin users remained below 12% before Medicare’s rule change. The American Diabetes Association now recommends CGM for every insulin regimen, yet primary-care inertia and cost hurdles slow translation into prescriptions. Type 1 patients total only 1.9 million but are adopting closed-loop technology at a rapid clip, driving a 14.46% forecast CAGR. DIY looping boosted time-in-range to 76% and cut severe hypoglycemia 54%, prompting insurers to reclassify CGM as standard-of-care.

Gestational diabetes represents the smallest slice, yet ACOG’s 2024 guidelines encourage CGM for insulin-treated pregnancies to reduce macrosomia, opening a nascent niche. Type 1 adoption exceeds 60% in urban centers where patient advocacy networks are robust. Type 2 uptake will accelerate as cost declines converge with employer wellness incentives, but SMBG will remain entrenched in diet- or oral-drug-managed populations. Gestational monitoring remains episodic, but it could shift to continuous monitoring if longitudinal outcome trials demonstrate lower neonatal ICU stays.

By End User: Diagnostic Centers Accelerate in Outpatient Pathways

Hospitals and clinics held 52.63% of United States blood glucose monitoring market size in 2025, benefiting from Joint Commission mandates for point-of-care testing and capitated readmission avoidance. FDA guidance now allows CGM in non-ICU beds, enabling remote nurse monitoring and trimming labor by USD 18 per patient-day. Diagnostic centers are expected to record a 15.13% CAGR as A1C testing bundles with same-day CGM initiation are favored by Medicare Advantage plans. Home care is the second-largest channel, leveraging telehealth CPT codes that reimburse clinicians USD 150-250 monthly for remote data reviews.

Electronic-health-record integration is a bottleneck; only 40% of hospitals had seamless CGM feeds in 2025. Quest and LabCorp's “test-to-treat” pilots reduce therapy initiation to seven days, demonstrating diagnostic-center agility. Rural broadband gaps still hamper home-upload models for 15% of households. Hospitals are piloting CGM-driven hypoglycemia early-warning systems that reduced code-blue events by 31% at Johns Hopkins in 2024. Diagnostic centers are therefore poised to capture a growing slice of the United States blood glucose monitoring market share as payers steer volume to controlled outpatient environments.

Geography Analysis

Florida, Arizona, and Pennsylvania collectively significant share of incremental CGM claims in the first year following Medicare’s coverage expansion, reflecting Medicare enrollment ratios above 20%. Southern states have prevalence rates exceeding 14% but lag in adoption, as Alabama and Mississippi each have fewer than three endocrinologists per 100,000 residents, compared to eight in Massachusetts. Medicaid prior authorization in Texas, Georgia, and North Carolina extends CGM approval by an average of 28 days, constraining penetration despite a high disease burden.

California, New York, and Texas account for 32% of national diabetes cases; all expanded Medicaid CGM coverage in 2024-25, but denial rates remain elevated, at 41% for initial Texas submissions. Integrated Midwest health systems such as Kaiser Permanente harmonize protocols across inpatient and outpatient sites, balancing SMBG and CGM utilization. Rural counties with limited broadband access experience a 62% lower CGM uptake and rely heavily on Bluetooth-only sensors, which lack real-time cloud uploads but satisfy patient privacy concerns.

Urban academic centers in Boston, San Francisco, and New York boast a CGM use rate of over 70% among Type 1 patients, driven by an early-adopter culture and alignment with insurers. Abbott, Dexcom, and Medtronic focus DTC campaigns in these Medicare-dense metros, leaving Medicaid-heavy rural zones understimulated. Without targeted investments in broadband and physician education, geographic inequity in the United States' blood glucose monitoring market is expected to widen through 2031.

Regulatory Landscape

Blood glucose monitoring systems in the United States are primarily regulated by the US Food and Drug Administration (FDA) as Class II devices, with self-monitoring blood glucose systems and continuous glucose monitoring (CGM) products typically entering the market via the 510(k) pathway under applicable device classifications (for example, BGMS under 21 CFR 862.1345). The FDA has also established interoperability-oriented categories (such as iCGM) that use special controls to support cross-vendor pairing of sensors and automated insulin delivery components, which helps shift the market toward modular device combinations rather than single-vendor lock-in.

In parallel, the FDA CLIA waiver framework remains important for home-use glucose monitoring adoption and retail-channel expansion, since it supports simpler use settings for qualified systems. Recent FDA activity in 2026 highlights continued throughput in near-patient and home-use glucose testing, including the June 2026 clearance of the cobas pulse blood glucose monitoring system and CLIA-waived clearances for additional branded BGMS offerings (for example, McKesson in April 2026 and a CVS Health Embrace TALKING system in March 2026). Alongside prescription CGM oversight, the FDA has also created dedicated consumer product codes for over-the-counter CGMs (as of 2024), supporting broader availability for non-traditional users beyond intensively managed insulin populations.

Market Opportunities and Future Outlook

A key whitespace in the United States blood glucose monitoring market is expanding monitoring beyond traditional insulin-intensive cohorts into earlier-risk and non-prescription pathways. OTC CGM approvals and consumer product codes created by the FDA (2024) reduce access friction, and the report context cites a large at-risk population (97.6 million adults with prediabetes). Market moves already underway reinforce this shift, including Dexcom's OTC Stelo pricing at USD 99 for a two-sensor month and Abbott securing US FDA clearance for OTC systems (Lingo and Libre Rio). Together, these create additional routes through pharmacies and direct-to-consumer models that are structurally different from durable medical equipment fulfillment, and can be paired with employer wellness and metabolic health programs.

Another opportunity centers on advancing interoperability and data-driven care workflows. FDA iCGM and related device classifications support cross-platform pump-sensor-controller combinations and align with patient-assembled closed-loop ecosystems. In clinical care, hospitals and outpatient pathways are increasing reliance on connected monitoring and remote review, supported by telehealth CPT codes for remote monitoring noted in the report context. At the same time, EHR integration remains a constraint, with only 40% of hospitals reporting seamless CGM feeds in 2025, leaving room for vendors that can simplify integration while addressing data-sharing preferences and privacy controls. On the product side, longer wear and next-generation sensing widen use-cases, including multi-analyte monitoring, as Abbott announced CE Mark progress for dual glucose-ketone sensing (Libre Duo) and an FDA submission, aligning with growing clinical attention to complications such as diabetic ketoacidosis.